Carotech Inc. (Edison, NJ) has entered into an exclusive license agreement with Metagenics, Inc. for the commercialization of Tocomin SupraBio—a patented, bio-enhanced, natural, full-spectrum palm tocotrienol complex—for North American healthcare practitioners.
Carotech will collaborate with Metagenics to formulate new products with Tocomin SupraBio, and to establish the best commercialization strategy for introducing this complex to healthcare practitioners.
The agreement allows Metagenics exclusivity to market Tocomin SupraBio, with an extension to extend this right subject to Metagenics’s achievement of certain performance criteria.
Metagenics (San Clemente, CA and Gig Harbor, WA), a privately held company, was founded in 1983 with the mission to help patients achieve their genetic potential through targeted nutrition. Metagenics markets its products to healthcare practitioners as innovative approaches to leading health issues.
WH Leong, vice president of Carotech Inc., hailed the agreement as recognizing the “commercial potential of Tocomin SupraBio in the healthcare practioner market.” Added Dr. Deanna Minich, director of technology and program integration at Metagenics, Inc., “Carotech’s Tocamin SupraBio is a superior source of tocotrienols and has been well-tested in several studies for its ability to protect nerve cells.”
The first Metagenics formula featuring Tocomin SupraBio will be a neurological support product for healthy brain function slated for a Fall 2006 launch. NIE
News published in Nutrition Industry Executive, October 2006